scholarly journals Detection of Recombinant Human Erythropoietin in Urine by Isoelectric Focusing

2003 ◽  
Vol 49 (6) ◽  
pp. 901-907 ◽  
Author(s):  
Andreas Breidbach ◽  
Don H Catlin ◽  
Gary A Green ◽  
Inna Tregub ◽  
Henry Truong ◽  
...  
Keyword(s):  
Isoelectric Focusing ◽  
Recombinant Human Erythropoietin ◽  
Time Course ◽  
Treated Group ◽  
Urine Samples ◽  
Epoetin Alfa ◽  
Band Ratio ◽  
Human Erythropoietin ◽  
Background Doping ◽  
Blood And Urine Samples

Abstract Background: Doping with erythropoietic proteins such as recombinant human erythropoietin (rHuEPO) and darbepoetin alfa is a serious issue in sport. There is little information on the time course of detection of rHuEPO in urine and on methods to evaluate electrophoresis-based data. Methods: We used a recently described isoelectric focusing method for detecting rHuEPO and endogenous EPO in urine obtained from individuals treated with placebo or epoetin alfa. The latter was administered subcutaneously at 50 IU/kg on days 0, 2, 4, 7, 9, 11, 14, 16, and 18. Blood and urine samples were collected during the morning of study days −3, 0, 2, 4, 7, 9, 11, 14, 16, and 18 and on days 2, 3, 4, and 7 postadministration. We developed visual and numerical (two-band ratio) techniques to evaluate the electropherograms for the presence of rHuEPO. Results: Compared with the placebo group, the epoetin alfa-treated group responded with increases in hematocrit, reticulocytes, macrocytes, serum EPO, and serum soluble transferrin receptor. The electropherograms showed that the pattern of bands arising from urinary rHuEPO is different from that of endogenous urinary EPO. Both the two-band ratio and the visual technique detected rHuEPO in all 14 epoetin alfa-treated individuals 3 days after the last dose. On the 7th day after the last dose, both techniques detected rHuEPO in approximately one-half of the participants. rHuEPO was not detected in the placebo-treated individuals. Conclusions: The isoelectric focusing method detects rHuEPO in most urine samples collected 3 days after nine doses of epoetin alfa. The numerical two-band ratio was equivalent to a visual method for detecting rHuEPO in urine.

scholarly journals Pharmacokinetics and the time course of pharmacodynamics of recombinant human erythropoietin (SNB-5001).

1991 ◽  
Vol 98 (2) ◽  
pp. 143-150 ◽  
Author(s):  
Hiroaki MASUNAGA ◽  
Reiko TAKAHIRA ◽  
Yukuo MURASE ◽  
Eisuke Tsuda ◽  
Tadanori SAWAI
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Time Course ◽  
Human Erythropoietin

Intraperitoneal Administration of Recombinant Human Erythropoietin

1992 ◽  
Vol 12 (4) ◽  
pp. 378-383 ◽  
Author(s):  
Leon A.M. Frenken ◽  
Dirk G. Struijk ◽  
Peter J.W. Coppens ◽  
Roland G.W.L. Tiggeler ◽  
Raymond T. Krediet ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Intraperitoneal Administration ◽  
Subcutaneous Administration ◽  
Hemoglobin Concentration ◽  
Treated Group ◽  
Efficacy And Safety ◽  
University Hospitals ◽  
Safe Alternative ◽  
Human Erythropoietin ◽  
Dialysis Solution

Objective To determine the efficacy and safety of intraperitoneal administration of recombinant human erythropoietin (rHuEPO) in continuous ambulatory peritoneal dialysis (CAPD) patients compared to subcutaneous rHuEPO. Design Prospective analysis of an open, nonrandomized investigation. Setting Outpatient CAPD clinics in two university hospitals. Patients Nine adult CAPD patients receiving rHuEPO intraperitoneally and 8 patients receiving rHuEPO sub-cutaneously. Intervention One hundred units of rHuEPO per kilogram of body weight were administered three times a week for 8 weeks or until the target hematocrit of 35% was reached. Thereafter, dosages of rHuEPO were adjusted for response. Intraperitoneal rHuEPO was administered in 1 L of dialysis solution during the night. Measurements Efficacy was assessed by measuring the increase in hemoglobin. Tolerance was assessed by monitoring side effects. Results In the first 8 weeks of treatment hemoglobin concentration increased from 64.5±12.9 glL to 98.3±16.1 g/L (p<0.0005) in the intra peritoneally treated group. In the subcutaneously treated group hemoglobin increased significantlyfaster (p<0.05) from 72.5±4.8 g/L to 119.2±11.3 g/L (p<0.0005) in the same period. Antihypertensive medication had to be increased or instituted in most of the patients in both groups. The incidence of peritonitis in the intraperitoneally treated group was not increased when compared to the pretreatment incidence. Conclusions Subcutaneously administered rHuEPO is superior to intraperitoneally administered rHuEPO with regard to the required dosages. However, the results of this study show that intraperitoneal administration of rHuEPO might be a convenient and safe alternative when subcutaneous administration is undesirable.

Detection of isoforms of recombinant human erythropoietin by various plant lectins after isoelectric focusing

2005 ◽  
Vol 26 (9) ◽  
pp. 1633-1645 ◽  
Author(s):  
Marietta Nagano ◽  
Gerald Stübiger ◽  
Martina Marchetti ◽  
Günter Gmeiner ◽  
Günter Allmaier ◽  
...  
Keyword(s):  
Isoelectric Focusing ◽  
Recombinant Human Erythropoietin ◽  
Plant Lectins ◽  
Human Erythropoietin

Interlaboratory method validation of imaged capillary isoelectric focusing methodology for analysis of recombinant human erythropoietin

2020 ◽  
Vol 12 (30) ◽  
pp. 3836-3843
Author(s):  
Xiang Li ◽  
Xingchang Shi ◽  
Xi Qin ◽  
Lei Yu ◽  
Yong Zhou ◽  
...  
Keyword(s):  
Method Validation ◽  
Isoelectric Focusing ◽  
Recombinant Human Erythropoietin ◽  
Capillary Isoelectric Focusing ◽  
Human Erythropoietin

Recombinant human erythropoietin (rhEPO) is one of the most important biopharmaceuticals worldwide, with global sales expected to reach US$11.9 billion in 2020.

Sign in / Sign up

Export Citation Format

Share Document